IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.
This study has been completed.
Sponsor:
Skane University Hospital
Collaborators:
Abbott
The Swedish Research Council
The Swedish Rheumatism Ass
Crafoord Foundation
Information provided by:
Skane University Hospital
ClinicalTrials.gov Identifier:
NCT01270087
First received: January 4, 2011
Last updated: NA
Last verified: January 2007
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether anti-inflammatory treatment with adalimumab (Humira) reduces endothelial activation in blood vessels in patients with active rheumatoid arthritis. Markers of endothelial activation are assessed in muscle tissue before treatment and after 3 months, and related to other biomarkers and clinical outcomes.
| Condition | Intervention | Phase |
|---|---|---|
| Rheumatoid Arthritis | Drug: Adalimumab | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study. |
Resource links provided by NLM:
Genetics Home Reference related topics:
rheumatoid arthritis
Drug Information available for:
Adalimumab
U.S. FDA Resources
Further study details as provided by Skane University Hospital:
Primary Outcome Measures:
- Endothelial expression of HLA-DQ in muscle biopsies [ Time Frame: 3 months ]Vascular tissue area stained for HLA-DQ by immunohistochemistry, quantified by computer assisted image analysis
- Endothelial expression of interleukin-1 alpha in muscle biopsies [ Time Frame: 3 months ]Vascular tissue area stained for interleukin-1 alpha by immunohistochemistry, quantified by computer assisted image analysis
- Carotid artery intima-media thickness [ Time Frame: 3 months ]Thickness of the intima and media of the common carotid artery, measured by ultrasound. Mean of two measures of the right and left common carotid artery.
| Enrollment: | 14 |
| Study Start Date: | May 2005 |
| Study Completion Date: | February 2007 |
| Primary Completion Date: | February 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Adalimumab |
Drug: Adalimumab
40 mg IV every 14 days
Other Name: Humira
|
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Clinical diagnosis of rheumatoid arthritis
- Fulfillment of the American College of Rheumatology 1987 criteria for rheumatoid arthritis
- Active disease despite treatment with at least one disease modifying anti-rheumatic drug
- Treatment with adalimumab indicated according to the the patient's rheumatologist
- At least six swollen joints in 28-joint index
- CRP > 8 mg / L within the last three months
Exclusion Criteria:
- Treatment with anti-TNF drugs in the last three months
- Treatment with intravenous corticosteroids within fourteen days
- Ongoing treatment with oral high-dose corticosteroids (equivalent to ≥ 20 mg of prednisolon daily) or completed such treatment less than fifteen days before inclusion
- Severe bleeding disorder
- Extensive or refractory leg ulcers
- Severe peripheral vascular disease
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01270087
Please refer to this study by its ClinicalTrials.gov identifier: NCT01270087
Locations
| Sweden | |
| Department of Rheumatology, Skåne University Hospital | |
| Malmö, Sweden, 205 02 | |
Sponsors and Collaborators
Skane University Hospital
Abbott
The Swedish Research Council
The Swedish Rheumatism Ass
Crafoord Foundation
Investigators
| Principal Investigator: | Carl Turesson, MD, PhD | Department of Rheumatology, Skåne University Hospital |
More Information
| Responsible Party: | Carl Turesson, Associate Professor, Department of Rheumatology, Skåne University Hospital |
| ClinicalTrials.gov Identifier: | NCT01270087 History of Changes |
| Other Study ID Numbers: |
REUMAUMAS 2005-1 2005-000129-47 ( EudraCT Number ) |
| Study First Received: | January 4, 2011 |
| Last Updated: | January 4, 2011 |
Keywords provided by Skane University Hospital:
|
Rheumatoid arthritis, cardiovascular disease, adalimumab |
Additional relevant MeSH terms:
|
Arthritis Arthritis, Rheumatoid Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Connective Tissue Diseases |
Autoimmune Diseases Immune System Diseases Adalimumab Anti-Inflammatory Agents Antirheumatic Agents |
ClinicalTrials.gov processed this record on August 16, 2017